Case CRS – ACTG Network

Location	Case Clinical Research Site 2061 Cornell Road Room 401 Cleveland OH 44106
CRS Coordinator	Julie Pasternak pasternak.julie@clevelandactu.org 216-844-2738
CRS Leader	Jeffrey M. Jacobson jxj573@case.edu 215-707-6451
Studies	A5322: Long-Term Follow-up of Older HIV-infected Adults in the ACTG: Addressing Issues of Aging, HIV Infection and Inflammation (HAILO) A5332: REPRIEVE Trial A5355: Phase II, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®) in Adults with Both Human Immunodeficiency Virus (HIV)-1 and CMV Who Are on Potent Combination ART with Conserved Immune Function A5357: A Study of Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) to Maintain Viral Suppression in Adults Living with HIV-1 A5361s: Pitavastatin to REduce Physical Function Impairment and FRailty in HIV (PREPARE) A5364: A Phase I, Open-Label Study of the Safety and Ability of Broadly Neutralizing Antibodies 3BNC117-LS and 10-1074-LS in Combination to Durably Prevent Viral Relapse During a Monitored Analytical Treatment Interruption A5368:Anti-PD-1 Antibody in HBV Infected on Suppressive Antiviral Therapy A5379: B-Enhancement of HBV vaccination in persons living with HIV (BEe-HIVe): Evaluation of HEPLISAV-B A5391: Doravirine for Persons with Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide (The Do IT Study) A5401: ACTIV-2 Outpatient Monoclonal Antibodies and Other Therapies A5418:Study of Tecovirimat for Human Monkeypox Virus (STOMP) ACTG A5383: Randomized, Controlled Trial to Evaluate the Anti-inflammatory Efficacy of Letermovir (Prevymis) in Adults with Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive ART and Its Effect on Chronic Inflammation, HIV Persistence, and Other Clinical Outcomes (ELICIT) ACTG A5359: Long-Acting Antiretroviral Therapy in Non-adherent Persons Living with HIV (PLWH)